Aims: To investigate the effect of an oral immunomodulation therapy with E. coli fractions on the frequency of urinary tract infections (UTIs) in patients with spinal cord injury (SCI) in a retrospective cohort study with a follow-up of 12 months.
Methods: The patient database of a tertiary urologic referral center was screened for patients with chronic (>12 months) SCI who were taking a lyophilized lysate of 18 E. coli strains from 2008 to 2016. Patient characteristics, annual number of patient-reported UTIs and urine culture results were collected. The change in the number of UTIs, categorized as no UTIs, sporadic UTIs (1-2/year) and recurrent UTIs (≥3/year), from before to during immunomodulation therapy was investigated. Furthermore, the effect of different possible confounders (eg, age, duration of SCI, use of catheters, and concurrent antibiotic treatment) was investigated.
Results: The data of 136 individuals with a mean age of 49 ± 14 years and a median time since SCI of 18 (15-22) years were analyzed. The proportion of patients with recurrent UTIs decreased significantly (P < 0.0001) from 93.4% (87.8-96.9%) to 59.6% (50.8-67.9%) during immunomodulation therapy, whereas the proportion of patients without UTIs increased significantly (P < 0.0001) from 2.2% (0.5-6.3%) to 20.6% (14.1-28.4%). The investigated confounders had no significant (P ≥ 0.15) effect on the outcome.
Conclusions: Oral immunomodulation therapy with E. coli fractions resulted in a significant and clinically relevant decrease in the frequency of UTIs in patients with SCI and thus, seems to be a promising option for the prevention of UTIs.
Keywords: E. coli; immunomodulation; immunostimulation; immunotherapy; neurogenic lower urinary tract dysfunction; spinal cord injury; urinary tract infection.
© 2018 Wiley Periodicals, Inc.